article Open AccessTop 1% cited
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Cancer Cell · 2004 · Vol. 6(2) · pp. 117–127
Yoichi Nagata(The University of Texas MD Anderson Cancer Center)Keng‐Hsueh Lan(The University of Texas MD Anderson Cancer Center)Xiaoyan Zhou(The University of Texas MD Anderson Cancer Center)Ming Tan(The University of Texas MD Anderson Cancer Center)Francisco J. Esteva(The University of Texas MD Anderson Cancer Center)Ayşegül A. Şahin(The University of Texas MD Anderson Cancer Center)Kristine S. Klos(The University of Texas MD Anderson Cancer Center)Ping Li(The University of Texas MD Anderson Cancer Center)Brett P. Monia(Ionis Pharmaceuticals (United States))Nina Nguyen(The University of Texas MD Anderson Cancer Center)Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center)Mien‐Chie Hung(The University of Texas MD Anderson Cancer Center)Dihua Yu✉(The University of Texas MD Anderson Cancer Center)
HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerMonoclonal and Polyclonal Antibodies ResearchTrastuzumabPTENCancer researchPI3K/AKT/mTOR pathwayBreast cancerMedicineCancerBiologyInternal medicineSignal transduction
MeSH terms
TrastuzumabPhosphoinositide-3 Kinase InhibitorsAnimalsAntibodies, MonoclonalAntineoplastic AgentsBreast NeoplasmsEnzyme ActivationEnzyme InhibitorsFemaleHumansMice, NudeNeoplasm TransplantationPhosphoric Monoester HydrolasesProto-Oncogene ProteinsGenes, Tumor Suppressor
Funding
- National Institutes of Health
Citations
1,856
FWCI
43.15
field-weighted impact
References
73
Percentile
100%
vs. same field & year
Citations per year
Cited by
The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
Journal of Medicinal Chemistry · 2008 · 741 citations
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Oncotarget · 2016 · 325 citations
ErbB receptors and signaling pathways in cancer
Current Opinion in Cell Biology · 2009 · 975 citations
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Nature Reviews Drug Discovery · 2005 · 2,158 citations
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Frontiers in Oncology · 2012 · 604 citations
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Nature reviews. Cancer · 2009 · 2,438 citations
PTEN: Multiple Functions in Human Malignant Tumors
Frontiers in Oncology · 2015 · 458 citations
Cancer drug resistance: an evolving paradigm
Nature reviews. Cancer · 2013 · 4,512 citations
References
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Journal of Clinical Oncology · 2002 · 2,949 citations
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
Science · 1987 · 11,680 citations
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Journal of Clinical Oncology · 1999 · 2,788 citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
New England Journal of Medicine · 2001 · 11,439 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.